Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.
Bril
Vera
V
Department of Medicine, University of Toronto, Ontario, Canada. vera.bril@utoronto.ca
Buchanan
Robert A
RA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy; D003929:Diabetic Neuropathies / Q000175:diagnosis* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004576:Electromyography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction; D011115:Polyneuropathies / Q000175:diagnosis / Q000188:drug therapy; D011336:Probability; D011719:Pyrazines / Q000627:therapeutic use*; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D013141:Spiro Compounds / Q000627:therapeutic use*; D013497:Sural Nerve / Q000187:drug effects* / Q000503:physiopathology; D016896:Treatment Outcome
D011719:Pyrazines; D013141:Spiro Compounds; D000449:Aldehyde Reductase; C115070:ranirestat